Searched for
CIPLA STOCK ANALYSIS
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...- Two Trades for Today: A pharma major for an 8.1% upmove, a mid-cap specialty chemical stock for a rise of about 6%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Most hated stocks: FIIs dumping these 146 companies without a break for 4 straight quarters. Do you own any?Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...
- Most difficult: Staying invested in businesses while ignoring noise called Gulf war; 19 stocks from different sectors to ‘hold’Businesses that create long-term wealth are those where the demand runway is long, the competitive position is strong, and the management i...
- Will the currency cycle help them? Yes, but very selectively: 10 pharma stocks with upside potential of up to 33%The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...
- Cipla shares slide 5% after temporary halt in key drug manufacturingCipla shares fell sharply on Friday after a halt in Lanreotide Injection production due to USFDA observations at its Greek partner. Supply ...
- 2 top stock recommendations from Rajesh Palviya for next weekEntering the August expiry week, Nifty faces a supply zone at 25,000–25,200, with potential consolidation above 24,800. Bank Nifty appears ...
- Two Trades for Today: A large-cap pharma company for an almost 7% gain, another for a 6% upmoveTechnical analysis identifies select stocks that may gain momentum even in volatile markets. Picks by the technical charts today.
- 2 top stock recommendations from Sneha SethSneha Seth from Angel One suggests booking profits for intraday positions in index options. She notes potential resistance at 23,000-23,100...
- F&O Radar | Deploy Bull Call Spread in Cipla for gains from bullish momentumCipla shares broke out from a falling trendline, signaling bullish momentum. A close above Rs 1,500 could drive prices to Rs 1,540–1,580. R...
- Stocks to buy today: Cipla, ONGC among top 9 trading ideas for 19 February 2025The Indian market is expected to consolidate on Wednesday, influenced by muted global cues. The Nifty futures closed slightly negative, wit...
- F&O Stock Strategy: How to trade Canara Bank, Cipla and CromptonWhile the overall market may remain in a consolidation mode for some time, there is potential for noteworthy stock-specific movements in th...
- BPCL, Coal India among 10 Nifty stocks with golden crossover patternOn September 20, Wednesday, Trendlyne uncovered an intriguing pattern in the stock market - the Golden Crossover. In this article, we delve...
- Stock Radar: Pharma stocks in focus! Cipla could retest record highs in short termShort-term traders can buy the stock for a possible short-covering move which could take the stock towards 1275 levels, suggest experts. Th...
- BPCL, Cipla among 10 Nifty stocks with golden crossover patternOn September 22, Friday, Trendlyne reported that more than 40 Nifty stocks experienced a Golden Crossover, a powerful indicator for traders...
- Coal India, HCL Technologies among 10 Nifty stocks with golden crossover patternThis article explores the significance of the Golden Crossover and why it's essential for investors to assess stock movements based on this...
- Indian Bank, Poonawalla Fincorp among 10 overbought stocks with RSI above 70In this article, we delve into the world of stock market analysis, focusing on the Relative Strength Index (RSI) and its pivotal role in un...
- M&M, Godrej Properties and 5 other stocks break above 200-day SMAIn technical analysis, when a stock's price surpasses its 200-day Simple Moving Average (SMA), it is seen as a bullish signal. Several stoc...
- In next 2-3 months, India more likely to underperform: Sandip Sabharwal“I would still be cautious through October because the typical parameters which define a sort of bottom formation in the US markets also do...
- Cipla movement under Sebi lensTHE SECURITIES and Exchange Board of India has initiated a probe into the price movement of pharma major Cipla prior to its inclusion in th...
Load More
